Shanghai Municipal Center for Disease Control and Prevention
11
1
1
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 40/100
9.1%
1 terminated/withdrawn out of 11 trials
83.3%
-3.2% vs industry average
36%
4 trials in Phase 3/4
20%
1 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Safety Study of Quadrivalent Subunit Influenza Vaccine in People Aged 3 Years and Older
Role: collaborator
Optimizing HPV Vaccine Introduction in Shanghai, China
Role: collaborator
Shanghai Community Prediabetes Standardized Management Project
Role: collaborator
Drug Exposure and Minimum Inhibitory Concentration in the Treatment of MAC Lung Disease
Role: collaborator
Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine Coadministered With Two Attenuated Vaccines
Role: lead
A Clinical Trial to Evaluate the Safety and Immunogenicity of PPV23 Vaccine Revaccinated in 60-70 Years Old
Role: collaborator
Evaluation of Immunogenicity and Safety of Combined Immunization of COVID-19 Vaccine (Produced in Beijing) and PPV23 / IIV4
Role: collaborator
Stool-based SDC2 DNA Methylation Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Role: collaborator
Systemic Redesign and Demonstration for Early Detection, Evaluation and Management of Chronic Kidney Disease in Shanghai
Role: collaborator
A National School-based Health Lifestyles Interventions Among Chinese Children and Adolescents Against Obesity
Role: collaborator
Study on Effectiveness of 2-dose Live Attenuated Varicella Vaccine
Role: lead
All 11 trials loaded